Zimmer Biomet Holdings Stock Earnings Reports

Q1 2026 highlights: Zimmer Biomet reported solid execution with net sales of $2.087B (reported +9.3%, organic constant-currency +2.9%) and adjusted EPS of $2.09 (+15% YoY). Results included a roughly $0.20 per-share tariff-related benefit that partially pulled forward margin upside. Management kept full-year organic revenue guidance at +1% to +3% (reported +2.5% to +4.5%), but raised 2026 adjusted EPS to $8.40–$8.55 and raised free cash flow growth guidance to 9%–11%. Key operational themes: (1) U.S. go-to-market commercial transformation is on plan (reducing nondedicated reps, increasing specialization), with early productivity gains in transitioned territories; (2) technology and data businesses are strong (nearly 12% growth for tech, bone cement and surgical; robotics and digital solutions showing rapid adoption), Monogram clinical enrollment is complete with a semiautomated U.S. launch expected early 2027 and fully autonomous later; (3) Paragon 28 integration is accelerating (Q1 growth accelerating vs. Q4 and trending toward double-digit); (4) margins expected to be modestly lower for the year (operating margins projected down slightly less than 50 bps vs. 2025) with second-quarter operating margin pressure; (5) leadership change — CFO Suketu Upadhyay is leaving and Paul Stellato will serve as interim CFO. Management remains “confident” in the strategy but is maintaining a conservative cadence in guidance given the ongoing transition and investments (U.S. commercial changes, technology launches and supply/distributor evolutions).